The phytocannabinoid-based medicine Sativex® is currently marketed for the treatment\nof spasticity and pain in multiple sclerosis patients and is being investigated for other central and\nperipheral pathological conditions. It may also serve in Veterinary Medicine for the treatment of\ndomestic animals, in particular for dogs affected by different pathologies, including human-like\npathological conditions. With the purpose of assessing different dosing paradigms for using Sativex\nin Veterinary Medicine, we investigated its pharmacokinetics when administered to naïve dogs\nvia sublingual delivery. In the single dose arm of the study, adult Beagle dogs were treated with\n3 consecutive sprays of Sativex, and blood samples were collected at 12 intervals up to 24 h later.\nIn the multiple dose arm of the study, Beagle dogs received 3 sprays daily for 14 days, and blood\nsamples were collected for 24 h post final dose. Blood was used to obtain plasma samples and..................
Loading....